Table 3. Correlation between clinicopathological characteristics and DUSP1 methylation in breast tumour DNA and PBL DNAa.
| Clinicopathologic characteristics |
DUSP1 methylation (tumour tissue DNA) |
DUSP1 methylation (PBL DNAa) |
||||||
|---|---|---|---|---|---|---|---|---|
| Methylated No. (%) | Unmethylated No. (%) | ORcrude (95% CI)b | P-value | Methylated No. (%) | Unmethylated No. (%) | ORcrude (95% CI)b | P-value | |
| TNM Stages | 0.886 | 0.327 | ||||||
| I | 38 (60.3) | 25 (39.7) | 1.000 | 8 (8.0) | 92 (92.0) | 1.000 | ||
| II | 113 (59.8) | 76 (40.2) | 0.978 (0.546–1.751) | 0.941 | 11 (4.7) | 221 (95.3) | 0.572 (0.223–1.469) | 0.246 |
| III & IV | 42 (56.8) | 32 (43.2) | 0.863 (0.436–1.709) | 0.674 | 3 (3.3) | 87 (96.7) | 0.397 (0.102–1.543) | 0.182 |
| Tumour invasion | 0.566 | 0.110 | ||||||
| T0–T1 | 86 (61.0) | 55 (39.0) | 1.000 | 13 (7.3) | 166 (92.7) | 1.000 | ||
| T2–T4 | 107 (57.8) | 78 (42.2) | 1.140 (0.729–1.782) | 9 (3.7) | 234 (96.3) | 0.491 (0.205–1.176) | ||
| Lymphnodes involved | 0.506 | |||||||
| N0 | 103 (60.9) | 66 (39.1) | 1.000 | 11 (5.2) | 201 (94.8) | 1.000 | ||
| N1/N3 | 90 (57.3) | 67 (42.7) | 1.162 (0.747–1.808) | 11 (5.3) | 197 (94.7) | 1.020 (0.432–2.408) | ||
| Metastasis status | 0.950 | 0.999 | ||||||
| M0 | 186 (59.2) | 128 (40.8) | 1.000 | 22 (5.4) | 389 (94.6) | |||
| M1 | 7 (58.3) | 5 (41.7) | 1.038 (0.322–3.343) | 0 (0.0) | 11 (100.0) | |||
| Histological type | 0.243 | 0.871 | ||||||
| Invasive | 143 (57.4) | 106 (42.6) | 1.000 | 17 (5.3) | 303 (94.7) | 1.000 | ||
| Noninvasive | 50 (64.9) | 27 (35.1) | 1.373 (0.807–2.335) | 5 (4.9) | 97 (95.1) | 0.919 (0.330–2.556) | ||
| ER status | 0.001 | 0.036 | ||||||
| Positive | 113 (52.8) | 101 (47.2) | 1.000 | 12 (3.8) | 301 (96.2) | 1.000 | ||
| Negative | 79 (71.8) | 31 (28.1) | 2.278 (1.389–3.7335) | 10 (9.2) | 99 (90.8) | 2.534 (1.062–6.044) | ||
| PR status | 0.003 | 0.013 | ||||||
| Positive | 94 (51.9) | 87 (48.1) | 1.000 | 9 (3.2) | 271 (96.8) | 1.000 | ||
| Negative | 98 (68.5) | 45 (31.5) | 2.016 (1.275–3.186) | 13 (9.2) | 129 (90.8) | 3.034 (1.264–7.282) | ||
| HER2 expression | 0.503 | 0.779 | ||||||
| Positive | 127 (60.5) | 83 (39.5) | 1.000 | 15 (5.4) | 261 (94.6) | 1.000 | ||
| Negative | 64 (56.6) | 49 (43.4) | 0.854 (0.537–1.357) | 7 (4.8) | 139 (95.2) | 1.141 (0.455–2.865) | ||
| Molecular subtypec | 0.001 | 0.108 | ||||||
| Luminal A | 33 (44.0) | 42 (56.0) | 1.000 | 3 (2.7) | 110 (97.3) | 1.000 | ||
| Luminal B | 81 (57.0) | 61 (43.0) | 1.690 (0.961–2.971) | 0.068 | 9 (4.4) | 197 (95.6) | 1.675 (0.444–6.317) | 0.446 |
| HER-2 enriched | 46 (67.6) | 22 (32.4) | 2.661 (1.345–5.267) | 0.005 | 6 (8.5) | 65 (91.5) | 3.385 (0.819–13.944) | 0.092 |
| Basal-like | 31 (81.6) | 7 (18.4) | 5.636 (2.205–14.406) | 0.000 | 4 (12.5) | 28 (87.5) | 5.238 (1.108–24.763) | 0.037 |
| P53 | 0.649 | 0.151 | ||||||
| Positive | 49 (61.2) | 31 (38.8) | 1.000 | 8 (8.1) | 91 (91.9) | 1.000 | ||
| Negative | 143 (58.4) | 102 (41.6) | 0.887 (0.529–1.487) | 14 (4.3) | 308 (95.7) | 0.517 (0.210–1.271) | ||
aPBL, peripheral blood leukocytes; bORcrude, odds ratio generated by univariate logistic regression; 95%CI, 95% confidence interval. cSubtypes were classified by immunohistochemical surrogates as basal-like (ER-, PR-, HER-2−, triple-negative), luminal A (ER and/or PR+, HER-2−), luminal B (ER and/or PR+, HER-2+), or HER-2 enriched (ER and PR−, HER-2+).